ATE361364T1 - Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen - Google Patents

Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen

Info

Publication number
ATE361364T1
ATE361364T1 AT97923243T AT97923243T ATE361364T1 AT E361364 T1 ATE361364 T1 AT E361364T1 AT 97923243 T AT97923243 T AT 97923243T AT 97923243 T AT97923243 T AT 97923243T AT E361364 T1 ATE361364 T1 AT E361364T1
Authority
AT
Austria
Prior art keywords
fibronectin
production
domain
antibodies
specific
Prior art date
Application number
AT97923243T
Other languages
German (de)
English (en)
Inventor
Dario Neri
Barbara Carnemolla
Annalisa Siri
Enrica Balza
Patrizia Castellani
Alessandro Pini
Luciano Zardi
Giovanni Neri
Laura Borsi
Original Assignee
Philogen Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen Spa filed Critical Philogen Spa
Application granted granted Critical
Publication of ATE361364T1 publication Critical patent/ATE361364T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
AT97923243T 1996-05-24 1997-05-23 Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen ATE361364T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9610967A GB9610967D0 (en) 1996-05-24 1996-05-24 Specific binding members,materials and methods

Publications (1)

Publication Number Publication Date
ATE361364T1 true ATE361364T1 (de) 2007-05-15

Family

ID=10794298

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97923243T ATE361364T1 (de) 1996-05-24 1997-05-23 Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen

Country Status (28)

Country Link
US (3) US7273924B1 (enExample)
EP (1) EP0906426B1 (enExample)
JP (2) JP4750912B2 (enExample)
KR (2) KR100741452B1 (enExample)
CN (1) CN100447159C (enExample)
AT (1) ATE361364T1 (enExample)
AU (1) AU729081B2 (enExample)
BG (1) BG65138B1 (enExample)
BR (1) BR9709350B1 (enExample)
CA (1) CA2256308C (enExample)
CZ (1) CZ295531B6 (enExample)
DE (1) DE69737683T2 (enExample)
DK (1) DK0906426T3 (enExample)
EA (1) EA004329B1 (enExample)
ES (1) ES2286831T3 (enExample)
GB (1) GB9610967D0 (enExample)
HU (1) HUP0200546A2 (enExample)
IL (2) IL127216A0 (enExample)
IS (1) IS2508B (enExample)
NO (1) NO324904B1 (enExample)
NZ (1) NZ333083A (enExample)
PL (1) PL188557B1 (enExample)
PT (1) PT906426E (enExample)
SI (1) SI0906426T1 (enExample)
SK (1) SK285916B6 (enExample)
TR (1) TR199802416T2 (enExample)
UA (1) UA74129C2 (enExample)
WO (1) WO1997045544A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US6685943B1 (en) 1997-01-21 2004-02-03 The Texas A&M University System Fibronectin binding protein compositions and methods of use
US7244826B1 (en) * 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US20030176663A1 (en) * 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
TWI259837B (en) * 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
WO2001062800A1 (en) * 2000-02-24 2001-08-30 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
JP4917232B2 (ja) * 2000-02-24 2012-04-18 フィロジェン ソチエタ ペル アツィオニ 病理学的病変における脈管形成の処理のための組成物及び方法
US7094750B2 (en) 2000-05-09 2006-08-22 Greenville Hospital System Therapeutic pore-forming peptides
AU2001281824A1 (en) * 2000-06-15 2001-12-24 Patrizia Castellani Methods for quantitative determination of b-fibronectin in biological fluids and tissues
HRP20030263A2 (en) * 2000-09-07 2005-10-31 Schering Aktiengesellschaft RECEPTOR IN THE ED<SUB>b</SUB>-FIBRONECTIN-DOMAIN
IT1317108B1 (it) * 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
US7456146B2 (en) * 2001-05-09 2008-11-25 Ghc Research Development Corporation Lytic peptide prodrugs
BR0306715A (pt) 2002-01-03 2004-12-28 Schering Ag Métodos para diagnóstico e tratamento de tumores
RU2347787C2 (ru) * 2002-03-11 2009-02-27 Филоджен С.П.А. Избирательный направленный перенос в сосудистую сеть опухоли с использованием молекул антител
SI2269656T1 (sl) 2002-07-15 2014-11-28 Board Of Regents, The University Of Texas System Izbrana protitelesa, ki se veĹľejo na aminofosfolipide, in njihova uporaba v zdravljanju raka
CA2518371A1 (en) 2003-03-14 2004-09-30 Wyeth Antibodies against human il-21 receptor and uses therefor
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
AU2005203962C1 (en) 2004-01-05 2012-11-08 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
ATE534750T1 (de) 2004-07-30 2011-12-15 Adeza Biomedical Corp Onkofetales fibronektin als zervixkarzinom-marker
US7785591B2 (en) * 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
EP1803814A1 (en) 2005-12-27 2007-07-04 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Method of improving the antibody selection capacity in phage-display library
EP1925664A1 (en) 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures
ES2382058T3 (es) 2008-01-17 2012-06-04 Philogen S.P.A. Combinación de una proteína de fusión de un anticuerpo dirigido contra el EDB de la fibronectina-IL-2, y una molécula de unión a los linfocitos B, progenitores de los linfocitos B y/o sus homólogos cancerosos
EP2100621A1 (en) 2008-03-10 2009-09-16 mivenion GmbH Polyether polyol dendron conjugates with effector molecules for biological targeting
EP2116555A1 (en) 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma
IT1392027B1 (it) * 2008-12-12 2012-02-09 Castellani Anticorpo monoclonale e suo uso per la identificazione della isoforma oncofetale della fibronettina (b-fn) a scopo diagnostico o terapeutico.
BR112012014417B1 (pt) 2009-12-14 2021-11-09 Scil Proteins Gmbh Proteínas ubiquitinas modificadas tendo uma atividade de ligação específica para o extradomínio b de fibronectina
WO2011110490A1 (en) 2010-03-09 2011-09-15 Bayer Pharma Aktiengesellschaft Process for the production of radioactively labelled scfv antibody fragments, kits and compositions
WO2012171541A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
JP6146821B2 (ja) 2011-06-15 2017-06-14 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングNavigo Proteins GmbH 修飾ユビキチンに基づく二量体型結合タンパク質
EP2861616A1 (en) 2012-06-13 2015-04-22 Scil Proteins GmbH Human fusion proteins comprising single chain tnfalpha and targeting domains
WO2014094799A1 (en) 2012-12-19 2014-06-26 Scil-Proteins-Gmbh Ubiquitin moieties as a means for prolonging serum half-life
WO2014194784A1 (zh) * 2013-06-06 2014-12-11 合肥立方制药股份有限公司 人源抗纤连蛋白ed-b结构域的抗体及其用途
WO2016124702A1 (en) 2015-02-06 2016-08-11 Scil Proteins Gmbh Novel egfr binding proteins
PL3322721T4 (pl) 2015-07-16 2022-06-06 Navigo Proteins Gmbh Nowe białka wiążące immunoglobulinę i ich zastosowanie w oczyszczaniu na bazie powinowactwa
WO2017013136A1 (en) 2015-07-20 2017-01-26 Scil Proteins Gmbh Novel binding proteins based on di-ubiquitin muteins and methods for generation
WO2017084017A1 (zh) * 2015-11-16 2017-05-26 合肥立方制药股份有限公司 Ed-b蛋白在诊断组织增生中的应用
US11813336B2 (en) 2016-05-04 2023-11-14 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
CA3030208A1 (en) 2016-08-11 2018-02-15 Navigo Proteins Gmbh Novel alkaline stable immunoglobulin binding proteins
EP4617283A2 (en) 2016-10-17 2025-09-17 Pfizer Inc. Anti-edb antibodies and antibody-drug conjugates
US11390666B2 (en) 2017-06-07 2022-07-19 Philogen S.P.A. Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
CN111148759B (zh) * 2017-09-30 2023-09-19 合肥立方制药股份有限公司 结合至纤维连接蛋白b结构域的蛋白
WO2019091918A1 (en) 2017-11-07 2019-05-16 Navigo Proteins Gmbh Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
EP3660039A1 (en) 2018-11-30 2020-06-03 Philogen S.p.A. Il2 immunoconjugates
WO2020070150A1 (en) 2018-10-02 2020-04-09 Philogen S.P.A Il2 immunoconjugates
JP2022544760A (ja) 2019-08-15 2022-10-21 ヤンセン バイオテツク,インコーポレーテツド 改善された単鎖可変断片のための材料及び方法
WO2021116337A1 (en) 2019-12-11 2021-06-17 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
CN111234016B (zh) * 2020-02-23 2021-09-07 北京康普美特创新医药科技有限责任公司 一种抗补体c5分子的全人源单克隆抗体及应用
CN111171149B (zh) * 2020-02-23 2021-09-07 北京康普美特创新医药科技有限责任公司 一种抗补体c5分子的人源化单链抗体及其应用
KR102614063B1 (ko) 2020-12-24 2023-12-19 대화제약 주식회사 엑스트라도메인 b 피브로넥틴에 특이적으로 결합하는 신규한 항체
CN118510535A (zh) 2022-01-04 2024-08-16 菲洛根股份公司 包含il-12的免疫细胞因子与激酶抑制剂的组合
US20250262307A1 (en) 2022-08-01 2025-08-21 Philochem Ag Conjugates of psma-binding moieties with cytotoxic agents
WO2024052333A1 (en) 2022-09-06 2024-03-14 Philochem Ag Multivalent fibroblast activation protein ligands for targeted delivery applications
WO2025061801A1 (en) 2023-09-19 2025-03-27 Philochem Ag Therapeutic combination of an anti-edb fibronectin domain antibody il2 or il12 fusion protein and a lutetium-177 radioconjugate
WO2025221736A2 (en) 2024-04-15 2025-10-23 Janssen Biotech, Inc. Ltbr binding molecules and uses thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
EP0460709B1 (en) 1985-01-28 1997-05-21 Xoma Corporation AraB promoters and method of producing polypeptides, including cecropins, by microbiological techniques
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4894326A (en) 1986-04-09 1990-01-16 Fred Hutchinson Cancer Research Center Monoclonal antibody defining oncofetal structure of fibronectin
US5243029A (en) * 1986-04-09 1993-09-07 Fred Hutchinson Cancer Research Center Oncofetal structure of fibronectin
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
EP0311434A3 (en) * 1987-10-09 1990-05-09 The De La Rue Company Plc Integrated circuit card
EP0396612B1 (en) 1988-01-11 1996-07-24 Xoma Corporation Novel plasmid vector with pectate lyase signal sequence
IT1217724B (it) * 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
US5177015A (en) 1988-08-12 1993-01-05 Fred Hutchinson Cancer Research Centre Onco-developmentally regulated α-N-acetylgalactosaminyltransferase
US5843156A (en) 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
JPH0276598A (ja) * 1988-09-14 1990-03-15 Fujita Gakuen 抗ed−b抗体
JPH04169195A (ja) * 1990-10-31 1992-06-17 Fujita Gakuen 抗ed―bモノクローナル抗体
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5629291A (en) 1992-01-31 1997-05-13 La Jolla Cancer Research Foundation Methods of modulating fibronectin extracellular matrix assembly
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6093399A (en) 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6036955A (en) 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US5976535A (en) 1992-06-09 1999-11-02 Neorx Corporation Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
US5561114A (en) 1992-09-25 1996-10-01 Otsuka Pharmaceutical Factory Inc. Adsorbent for cellular fibronectin, a method for fractional purification of fibronectin and a method of hemocatharisis
US5491130A (en) 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US6015897A (en) 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
US5523229A (en) 1994-03-22 1996-06-04 Trustees Of The University Of Pennsylvania Antibodies specific for oncofetal fibronectin
DE4417865A1 (de) 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
ITFI940095A1 (it) 1994-05-23 1995-11-23 Molteni & C Coniugati fotodinamici aventi proprieta' biocide
US5648485A (en) 1994-10-26 1997-07-15 University Of British Columbia β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
WO1996023816A1 (en) 1995-02-01 1996-08-08 British Technology Group Limited Radiolabelled proteins
WO1997002479A2 (en) 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US5808146A (en) 1995-11-09 1998-09-15 Emory University Amino acid analogs for tumor imaging
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US5913884A (en) 1996-09-19 1999-06-22 The General Hospital Corporation Inhibition of fibrosis by photodynamic therapy
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6394952B1 (en) 1998-02-03 2002-05-28 Adeza Biomedical Corporation Point of care diagnostic systems
US6267722B1 (en) 1998-02-03 2001-07-31 Adeza Biomedical Corporation Point of care diagnostic systems
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
WO2001062800A1 (en) 2000-02-24 2001-08-30 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
JP4917232B2 (ja) 2000-02-24 2012-04-18 フィロジェン ソチエタ ペル アツィオニ 病理学的病変における脈管形成の処理のための組成物及び方法
BR0306715A (pt) 2002-01-03 2004-12-28 Schering Ag Métodos para diagnóstico e tratamento de tumores
JP4169195B2 (ja) * 2003-06-24 2008-10-22 株式会社河合楽器製作所 電子楽音発生装置の記録制御装置

Also Published As

Publication number Publication date
SK285916B6 (sk) 2007-11-02
US20080274099A1 (en) 2008-11-06
JP4750912B2 (ja) 2011-08-17
CZ381598A3 (cs) 1999-03-17
UA74129C2 (uk) 2005-11-15
EP0906426B1 (en) 2007-05-02
AU2910197A (en) 1998-01-05
CN1219968A (zh) 1999-06-16
SK161298A3 (en) 1999-07-12
BG65138B1 (bg) 2007-03-30
AU729081B2 (en) 2001-01-25
EP0906426A1 (en) 1999-04-07
TR199802416T2 (xx) 1999-02-22
IL127216A (en) 2008-11-26
DK0906426T3 (da) 2007-09-10
PL330075A1 (en) 1999-04-26
ES2286831T3 (es) 2007-12-01
CZ295531B6 (cs) 2005-08-17
SI0906426T1 (sl) 2007-10-31
CA2256308C (en) 2012-03-13
BG102950A (en) 1999-08-31
US7273924B1 (en) 2007-09-25
EA004329B1 (ru) 2004-04-29
KR20050010081A (ko) 2005-01-26
IL127216A0 (en) 1999-09-22
CN100447159C (zh) 2008-12-31
JP2000511416A (ja) 2000-09-05
DE69737683T2 (de) 2008-01-10
US20140134182A1 (en) 2014-05-15
US9096670B2 (en) 2015-08-04
KR20060035812A (ko) 2006-04-26
BR9709350A (pt) 2000-01-04
IS4883A (is) 1998-10-29
WO1997045544A1 (en) 1997-12-04
PT906426E (pt) 2007-07-23
US8703143B2 (en) 2014-04-22
JP2009050261A (ja) 2009-03-12
HUP0200546A2 (en) 2002-07-29
NO985459L (no) 1999-01-22
BR9709350B1 (pt) 2010-12-14
DE69737683D1 (de) 2007-06-14
PL188557B1 (pl) 2005-02-28
KR100741452B1 (ko) 2007-07-20
IS2508B (is) 2009-04-15
GB9610967D0 (en) 1996-07-31
HK1020990A1 (zh) 2000-05-26
CA2256308A1 (en) 1997-12-04
EA199801043A1 (ru) 1999-04-29
NO985459D0 (no) 1998-11-23
NO324904B1 (no) 2007-12-27
NZ333083A (en) 2000-05-26

Similar Documents

Publication Publication Date Title
ATE361364T1 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
FR2724182B1 (fr) Obtention d&#39;un anticorps monoclonal recombinant a partir d&#39;un anticorps monoclonal humain anti-rhesus d, sa production en cellules d&#39;insecte, et ses utilisations
ATE377027T1 (de) Tetravalente antikörperkonstrukte
CY1112101T1 (el) Νευροτροφικοι παραγοντες
AU5055593A (en) Antibodies specific for HIV
DE69433406D1 (de) Antikörper gegen cd40
ES2177632T3 (es) Purificacion de anticuerpos.
CY1105836T1 (el) 12, 13-τροποποιημενα παραγωγα εποθιλονης
DE69939820D1 (de) Internalisierende erbb2 antikörper
BR9808491A (pt) Compostos calcilìticos
FI964845L (fi) CD44v6:n vastaiset monoklonaaliset vasta-aineet
DE60017019D1 (de) Antikörper gegen Spaltprodukte von Vimentin
PT840620E (pt) Antagonistas de il-8 para o tratamento de asma
EA200200974A1 (ru) Моноклональные антитела к рецептору лпнп человека, их получение и применение
DE69728897D1 (de) Saeugetierchemokine
DE50114321D1 (de) REZEPTOR DER EDb-FIBRONEKTIN-DOMÄNE (II)
DE59605545D1 (de) Alkoholhaltige instant-getränkemischung, ihre herstellung und verwendung
DE69838645D1 (de) Epitope der gp120 v1/v&#34; domäne von hiv-1 geeignet zur herstellung neutralisierender antikörper
DE60042273D1 (de) Antitumorantikörper, proteine und deren verwendung
DE69434087D1 (de) ENTEROTOXINE VON SHIGELLA FLEXNERI 2a
DE59611293D1 (de) Protein mit dnase-aktivität
EA200000705A1 (ru) Промежуточные соединения и способ синтеза 17-замещенных 16.бета.-арилокси 4-азастероидов
TW288020B (en) Monoclonal antibodies specific to methamphetamine, hybridoma producing the antibodies, kits containing the antibodies and uses thereof
EA199800028A1 (ru) Винилсульфоксиды и способы их синтеза
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0906426

Country of ref document: EP